about
Performance enhancement at the cost of potential brain plasticity: neural ramifications of nootropic drugs in the healthy developing brainImpact of contextual factors and substance characteristics on perspectives toward cognitive enhancementα7 nicotinic ACh receptors as a ligand-gated source of Ca(2+) ions: the search for a Ca(2+) optimumFunctional analysis of a novel positive allosteric modulator of AMPA receptors derived from a structure-based drug design strategyAMPAKINE enhancement of social interaction in the BTBR mouse model of autismTranslational animal models of autism and neurodevelopmental disorders.Pharmacological enhancement of memory or cognition in normal subjectsEffects of non-pharmacological or pharmacological interventions on cognition and brain plasticity of aging individuals.The NMDA receptor as a target for cognitive enhancementModafinil increases the latency of response in the Hayling Sentence Completion Test in healthy volunteers: a randomised controlled trialAlzheimer's disease and age-related memory decline (preclinical)AMPA receptor potentiators: from drug design to cognitive enhancementModulation of fronto-cortical activity by modafinil: a functional imaging and fos study in the rat.Memory enhancement: consolidation, reconsolidation and insulin-like growth factor 2Mechanisms of memory enhancementNavigating the enhancement landscape. Ethical issues in research on cognitive enhancers for healthy individuals.Impact of Astroglial Connexins on Modafinil Pharmacological Properties.The effects of methylphenidate on cognitive performance of healthy male rats.SAMP8 mice have altered hippocampal gene expression in long term potentiation, phosphatidylinositol signaling, and endocytosis pathways.Are AMPA receptor positive allosteric modulators potential pharmacotherapeutics for addiction?Differences between synaptic plasticity thresholds result in new timing rules for maximizing long-term potentiation.Nicotinic modulation of intrinsic brain networks in schizophrenia.The Biology of Forgetting-A Perspective.Emotional Modulation of Learning and Memory: Pharmacological Implications.Enhancement policy and the value of information.Ampakine CX717 potentiates intermittent hypoxia-induced hypoglossal long-term facilitation.Functional insight into development of positive allosteric modulators of AMPA receptors.Mechanism based approaches for rescuing and enhancing cognition.PWZ-029, an inverse agonist selective for α₅ GABAA receptors, improves object recognition, but not water-maze memory in normal and scopolamine-treated rats.Cognitive-enhancing substance use at German universities: frequency, reasons and gender differences.Rigor and Reproducibility in Rodent Behavioral Research.Insulin-Like Growth Factor II Targets the mTOR Pathway to Reverse Autism-Like Phenotypes in Mice.Neuroethical issues in pharmacological cognitive enhancement.Modafinil augments brain activation associated with reward anticipation in the nucleus accumbens.Electrophysiological Techniques for Studying Synaptic Activity In Vivo.7-Phenoxy-Substituted 3,4-Dihydro-2H-1,2,4-benzothiadiazine 1,1-Dioxides as Positive Allosteric Modulators of α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA) Receptors with Nanomolar Potency.Ameliorative Effect of Ginsenoside Rg1 on Lipopolysaccharide-Induced Cognitive Impairment: Role of Cholinergic System.Gastrodin Attenuates Cognitive Deficits Induced by 3,3'-Iminodipropionitrile.Everyday memory: towards a translationally effective method of modelling the encoding, forgetting and enhancement of memory.Cognitive enhancement in Canadian medical students.
P2860
Q21129314-B3F33C2E-DB58-4ED4-84A6-794252FCF2BCQ21558807-9F89740A-E50A-49AA-9B67-6C03297C1C72Q26852967-F798E52D-6355-40C1-A8D4-9CE0F4B676EBQ27681406-17309F67-ADCB-4B97-AC9A-777D55691B14Q28388762-766011A2-0C0B-459B-A42E-30D26F48229CQ30459992-0125C874-BAE7-4FD0-964F-E6E4A964307FQ33659760-29F7F5E4-76C3-4E3D-97B1-BCEDDD6FDEC1Q34118141-F977DDB7-4479-4F5B-9F81-D74601872F8EQ34288139-85C09EA9-C168-4DAE-8C7A-1D24A12E55AEQ34497399-7799AA5C-3B65-4C28-B1E4-89AF13835B69Q35041190-EB89190B-03EF-4503-8DCF-0FC8369CD44BQ35054673-A8D35086-BE1F-4DEC-ACC0-9ED9E6AD7629Q35679970-A260B4B8-F69E-4DEC-AB12-5E32EB79FE03Q35947060-BF8EF1DF-B30B-4971-AE25-67B6E55E4819Q36481055-5723E343-D474-4727-88D9-2ABBF95720EBQ36594188-673CE3E9-63E7-4200-A36E-2E1066585551Q36890146-A1D584C5-7373-44E8-903B-7AACC5EE6497Q36923712-9FA4E9DF-58B8-4643-8154-54E8538C6BFEQ37340286-4AC3C4B4-50EE-49D7-9A6D-FABB3C172E9DQ37559271-495445B2-FD6B-4800-BDCF-7614BD951CE3Q38028275-280A0911-BFCD-4788-8AF9-FE52BE0594D3Q38116676-C3DBD6C3-9615-4894-AA61-E60F74807F6AQ38429452-1464069D-02AC-4C57-8A82-58608CA12530Q39249414-4766AF39-1C7B-4A69-AA58-9DC6342D85CEQ39402334-89E60EC6-06E4-409E-ACAB-8B93B087A659Q39680708-4525C25A-6414-46E6-935B-35FB6E432DFDQ41784821-50D23F6C-CDF5-4A1C-A76D-2A4AB39B7AE0Q42555375-896596FB-DF92-47B7-AB66-242FB03E9474Q43010929-AC72DD06-5EC8-430A-B976-3CA0FEEF9C91Q44462460-FEDAE621-9F65-499F-8B0F-71C899794171Q47200848-2EE2D53C-E268-401F-A049-ADA5A7CFBCC8Q47582921-25D1BB7B-F18B-46BA-9F76-014DC688D90DQ47620390-B8633686-2854-4D44-8D14-636E26391226Q47784460-2E389C89-D885-4912-933D-4075B0FD6DEDQ47931622-DED38320-B8F5-4FEC-88F1-B1E7F73DBE96Q48095397-9E6B067F-F83C-42B5-9B4D-815913AF8467Q48361648-26DA6943-21E6-4B79-9720-1A91512E5613Q48912906-B4CBE34C-CD87-420A-BA37-48E8D0842943Q50433260-32D73BB5-9E6E-4D33-B07C-28257BD11AA6Q50866549-4A5FFBC8-0D3A-46FF-805E-AB9E874D064F
P2860
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
The likelihood of cognitive enhancement
@en
type
label
The likelihood of cognitive enhancement
@en
prefLabel
The likelihood of cognitive enhancement
@en
P2093
P2860
P1476
The likelihood of cognitive enhancement
@en
P2093
Christine M Gall
Gary Lynch
Linda C Palmer
P2860
P304
P356
10.1016/J.PBB.2010.12.024
P407
P577
2011-01-06T00:00:00Z